Johnson & Johnson, a worldwide leader in multiple myeloma, announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI^® (teclistamab) plus daratumumab in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1-3 prior lines of therapy.

In an analysis to be presented in Abstract #OA-58, statistical modelling estimated that more than 85% of patients treated with teclistamab plus daratumumab may experience a mortality risk and projected life expectancy similar to an age-matched general population. The analysis used a relative survival mixture cure model (MCM) and actual progression-free survival (PFS) and overall survival (OS) data from MajesTEC-3. Modelling further predicted that median OS with teclistamab plus daratumumab would be nearly four-fold longer than with the standard-of-care comparator in the study, daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd). These data help to illustrate to what extent treatment with teclistamab plus daratumumab as early as second line may reshape survival expectations in multiple myeloma.

Post-hoc analysis provides insight into the survival benefit

In the MajesTEC-3 study, teclistamab plus daratumumab significantly improved OS versus SOC, with an estimated 83% of patients alive at three years.² A post hoc analysis (Abstract #OA-49) showed that teclistamab plus daratumumab reduced the risk of cumulative incidence of disease progression by 90% versus SOC, with no significant difference in non-relapse mortality over time between the treatment arms.²

These data will be presented in two oral sessions at the International Myeloma Society (IMS) Annual Meeting.

Complementary mechanisms of action underpin this immunotherapy doublet

Teclistamab and daratumumab work in a complementary manner, with daratumumab modulating the immune system to enhance T-cell fitness and activation, thereby amplifying teclistamab-mediated killing of myeloma cells.

Expert and company perspectives emphasise the potential for durable, long-term disease control

“These findings underscore how consequential treatment choice at first relapse can be in shaping a patient’s long-term trajectory,” said Dr. Luciano J. Costa, Professor of Multiple Myeloma and Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama at Birmingham.* “The sustained disease control observed with teclistamab plus daratumumab is changing expectations for what treatment can achieve in relapsed or refractory multiple myeloma, moving beyond just delaying the next relapse toward the possibility of durable long-term disease control.” 

“Seeing projected life expectancy for patients with relapsed or refractory multiple myeloma potentially approach that of the general population is an exciting and hopeful signal of what may be possible with teclistamab plus daratumumab,” said Ester in ‘t Groen, EMEA Therapeutic Area Head, Haematology, Johnson & Johnson. “Alongside the growing body of positive clinical evidence, these analyses reinforce our convictions that this combination offers a new standard of care – one where outcomes once considered difficult to imagine could become increasingly achievable for patients.”

“The continued analyses of the MajesTEC-3 trial challenge long-held expectations of what may be possible in multiple myeloma,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. “Our ambition is to build on this progress by fundamentally changing the long-term trajectory of multiple myeloma and, ultimately, creating a future in which this disease is no longer defined as incurable.”